Fundz

Fundz Deep Dive

Everything you need to win HOPO Therapeutics — in one platform.

Who to reach, what to say, and why now on HOPO Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on HOPO Therapeutics — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

HOPO Therapeutics Awarded $226 Million Contract from BARDA for Advanced Development of Oral Decorporation Agent

Oct 28, 2024•over 1 year ago

Contract Type

contract

BerkeleyManufacturingBiotechnology

Description

HOPO Therapeutics, Inc. has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of the drug candidate HOPO-101 as a medical countermeasure against radiological threats. The funds will be used for toxicology and pharmacology studies, manufacturing activities, and nonclinical research in heavy metal poisoning, with additional funding available for later-stage development upon agreement between BARDA and HOPO.

Company Information

Company

HOPO Therapeutics

Location

Berkeley, California, United States

About

HOPO Therapeutics, Inc. is a company focused on developing decorporation agents for heavy metal toxicity, with a mission to provide rapid access to treatment for an exposed population during radiological or nuclear disasters.

Predictive Intelligence
Strategic

ML-powered predictions for HOPO Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.